Sign In
Buy ABCL
$5.63
-0.110 (-1.92%)
At Close: Jun 23, 2026
JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapies
11:31am, Thursday, 18'th Jun 2026
Jazz Pharmaceuticals teams up with AbCellera to discover and develop T-cell-engaging antibodies for GI cancers and other solid tumors.
Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration
12:54pm, Wednesday, 17'th Jun 2026
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) announced on Wednesday a collaboration with AbCellera Biologics Inc. (NASDAQ:ABCL) to discover next-generation T-cell-engaging multispecific antibodies.
Is ABCELLERA BIOLG (ABCL) Outperforming Other Medical Stocks This Year?
10:40am, Wednesday, 17'th Jun 2026
Here is how AbCellera Biologics Inc. (ABCL) and Agilon Health (AGL) have performed compared to their sector so far this year.
Jazz Pharma, AbCellera ink antibody deal worth up to $876 million
07:43am, Wednesday, 17'th Jun 2026
Jazz Pharmaceuticals has signed a research collaboration and licensing agreement with Canada's AbCellera to develop T-cell engaging multispecific antibodies for cancer, the companies said on Wed
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
07:00am, Wednesday, 17'th Jun 2026
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and AbCellera (Nasdaq: ABCL) today announced a preclinical research collaboration, option and license
AbCellera: An AI-Era Antibody Platform Trading For Little More Than Its Cash
06:33am, Wednesday, 17'th Jun 2026
AbCellera, an antibody platform behind two authorized COVID-19 therapies, has rebuilt itself into a clinical-stage biotech and is one quarter away from pivotal Phase 2 data on its first wholly-owned.
AbCellera: Q3 Hot Flashes Data Drop Aside, This Stock Is A Difficult Sell
09:18am, Tuesday, 09'th Jun 2026
AbCellera Biologics Inc. remains rated Hold, with valuation concerns outweighing near-term pipeline catalysts despite recent share price volatility. ABCL635, targeting hot flashes, is advancing to a P
Wall Street Analysts Think ABCELLERA BIOLG (ABCL) Could Surge 85.59%: Read This Before Placing a Bet
10:56am, Monday, 08'th Jun 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 85.6% in ABCELLERA BIOLG (ABCL). While the effectiveness of this highly sought-after metric is questionable, th
AbCellera Biologics Inc. (ABCL) Presents at Jefferies Global Healthcare Conference 2026 Transcript
03:12pm, Friday, 05'th Jun 2026
AbCellera Biologics Inc. (ABCL) Presents at Jefferies Global Healthcare Conference 2026 Transcript
AbCellera Appoints Dr. Victor Sandor to its Board of Directors
10:00am, Friday, 05'th Jun 2026
[url="]AbCellera[/url] (Nasdaq: ABCL) today announced the appointment of Victor Sandor, M.D.C.M, to its Board of Directors as an independent director. âDr.
AbCellera Appoints Dr. Victor Sandor to its Board of Directors
09:00am, Friday, 05'th Jun 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Appoints Dr. Victor Sandor to its Board of Directors.
AbCellera Biologics Bets on Hot Flash Antibody as Pipeline Pivot Gains Steam
01:02pm, Thursday, 04'th Jun 2026
AbCellera Biologics NASDAQ: ABCL is emphasizing its transition from a partner-based antibody discovery business to a proprietary drug development company, Chief Financial Officer Andrew Booth said dur
Has ABCELLERA BIOLG (ABCL) Outpaced Other Medical Stocks This Year?
10:42am, Monday, 01'st Jun 2026
Here is how AbCellera Biologics Inc. (ABCL) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.
After Golden Cross, AbCellera Biologics Inc. (ABCL)'s Technical Outlook is Bright
10:55am, Friday, 29'th May 2026
From a technical perspective, AbCellera Biologics Inc. (ABCL) is looking like an interesting pick, as it just reached a key level of support. ABCL's 50-day simple moving average crossed above its 200-
Wall Street Analysts Believe ABCELLERA BIOLG (ABCL) Could Rally 97.28%: Here's is How to Trade
10:56am, Friday, 22'nd May 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 97.3% in ABCELLERA BIOLG (ABCL). While the effectiveness of this highly sought-after metric is questionable, th
